Speciality packaging maker Rexam REX.L said it would sell the bulk of its healthcare business to Montagu Private Equity for $805 million in cash, seven months after it put the unit on the block to focus solely on making beverage cans.
The company's beverage cans business, which accounted for about 90 percent of sales last year, is expected to benefit from a spurt in demand ahead of the Soccer World Cup in Brazil this year and the Olympics in 2016.
Rexam is still looking for a buyer for its closures and containers unit - the part of its healthcare business that makes plastic bottles for over-the-counter medicine. (link.reuters.com/vas56v)
Even after the sale of the remaining unit, Rexam would fall short of analysts' expected target of $1 billion from the sale of the entire healthcare business, Macquarie Research analyst Al Kabili told Reuters.
"That's the least attractive business, like the lowest margin of the healthcare assets, so that's going to fetch the lowest price," Kabili said.
Jefferies & Co analyst Sandy Morris told Reuters that trading had been challenging in the closures and containers unit for the last four years. He estimated the unit would fetch about 50-70 million pounds ($82-$115 million).
Reuters reported in January that Montagu was in talks to buy Rexam's pharmaceutical devices and prescription retail packaging units, which make medical packaging and drug delivery devices such as bronchial inhalers and injection syringes.
The healthcare business was also pursued by German medical supplier Gerresheimer (GXIG.DE), U.S. packagers Berry Plastics Group Inc (BERY.N) and Silgan Holding Inc (SLGN.O), and private equity firms Bain Capital LLC and KKR & Co LP (KKR.N).
Rexam on Monday said it said it intended to return about 450 million pounds from the proceeds of the sale to shareholders.
The sale, expected to close around the middle of the year, leaves Rexam to focus on its business of making cans for companies including Coca-Cola Co (KO.N), PepsiCo Inc (PEP.N) and Heineken (HEIN.AS).
Rexam said it would focus on growing sales in emerging markets, which accounted for about a third of revenue in 2012. (r.reuters.com/nas56v)
The London-listed company said it expects strong sales from countries such as Brazil and India this year.
The company's stock was trading up about 1.7 percent at 501.5 pence at 1457 GMT. The stock has risen almost 5 percent since Rexam announced plans to sell the healthcare business.
The loan financing on the deal is expected to total around $600 million, sources told Reuters Loan Pricing Corporation on Monday.
Credit Suisse and Morgan Stanley are leading the deal with Credit Suisse coordinating senior loan facilities and Morgan Stanley co-ordinating second lien facilities, according to RLPC.
Rexam said Barclays was its financial adviser.
(Additional reporting by Sarah Young in London; Editing by Kate Holton, Gopakumar Warrier and Savio D'Souza)